Dr. Chris Rundfeldt looks back on 22 years of experience in drug development, with more than 13 years in pharmaceutical industry. He gained hands on experience in different fields of pharmacology including target validation, drug development, toxicology, and early clinical development. As co-founder and vice president pharmacology, he actively participated in the management buyout of Elbion AG, a biopharmaceutical company dedicated to the development of CNS active drugs and immune modulators. He was responsible for translation of pharmacological results and safety data into clinical study programs. In 1996 he obtained the German Board certification for Veterinary Pharmacology and Toxicology. In 2000, he was granted the venia legendi (Assistant Professor) for Veterinary Pharmacology and Toxicology at the Free University of Berlin. Since 2007, he has been working as independent drug development consultant and partner at DrugConsult.Net, a German development expert partnership.